JBJoseph M. Brandwein

Joseph M. Brandwein

*This is an algorithmically generated author record based on publicly available information.

Joseph M. Brandwein has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Differential survival improvement for patients 20–29 years of age with acute lymphoblastic leukemia

    by Jason D. Pole, Denise Darmawikarta, Shabbir M.H. Alibhai, Joseph M. Brandwein, Lillian Sung


  • Open Access

    Treatment of Philadelphia chromosome‐positive acute lymphoblastic leukaemia with imatinib combined with a paediatric‐based protocol

    by Santhosh Thyagu, Mark D. Minden, Vikas Gupta, Karen W.L. Yee, Aaron D. Schimmer, Andre C. Schuh, Jeffrey H. Lipton, Hans A. Messner, Wei Xu, Joseph M. Brandwein

    Although the combination of tyrosine kinase inhibitors with chemotherapy is widely used for young adults with Philadelphia chromosome positive‐acute lymphoblastic leukaemia (Ph+ ALL), the outcome and safety of this combination using intensive paediatric‐based protocols has not been well described. The clinical course of 32 adults age 18–60 years with Ph+ ALL treated with a paediatric‐based protocol plus imatinib was evaluated. The complete response rate was 94%. Grade 3–4 infections, neuropathy, myopathy and liver function abnormalities were common, resulting in major treatment delays and dose reductions, and declines in performance status (physical deconditioning), particularly in patients aged 41–60 years. Median and 3‐year overall survival (OS) was 40·7 months and 53%, respectively, and median and 3‐year even‐free survival (EFS) was 30·1 months and 50%, respectively. OS and EFS were inferior in deconditioned patients. Of 16 patients who underwent haematopoietic stem cell transplantation (HSCT) in first complete remission, six died of non‐relapse complications. There was no significant difference in OS and EFS between transplanted and non‐transplanted patients, based on an intention‐to‐treat and time‐to‐donor identification analysis. The combination of imatinib with a paediatric‐based regimen in adults produced high response rates, but was associated with considerable toxicity and high non‐relapse mortality post‐HSCT.


  • Open Access

    Therapy‐related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis

    by Amal Abdulwahab, Jenna Sykes, Suzanne Kamel‐Reid, Hong Chang, Joseph M. Brandwein

    BACKGROUND: Acute lymphoblastic leukemia (ALL) occurring in patients with a history of prior chemotherapy/radiotherapy exposure has been previously reported to be rare, accounting for MLL rearrangements, and 4 were BCR‐ABL+. MLL rearrangements were correlated with CD15 expression and absence of CD10, and also tended to have a shorter mean latency period and more prior topoisomerase II exposure. Twenty‐one patients received induction therapy, and 18 (86%) achieved a complete response, 17 with 1 induction. Six patients have relapsed and died, and 4 others died of other complications, 2 of these postallogeneic stem cell transplantation. Median disease‐free survival (DFS) and overall survival (OS) were 27 and 13.6 months, respectively, and 3‐year DFS and OS were 37.1% and 37.6%, respectively.CONCLUSIONS: The frequency of therapy‐related ALL is higher than previously reported and has a poor prognosis, probably related to the high frequency of adverse risk features. Cancer 2012. © 2011 American Cancer Society.


  • Treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults

    by Joseph M. Brandwein

    Treatment approaches for adolescents and young adults with acute lymphoblastic leukemia (ALL) have evolved considerably in the past 5–7 years. One of the major changes has been the widespread adoption of pediatric-based protocols, which appears to have significantly improved survival and probably renders allogeneic hematopoietic stem cell transplantation (HSCT) unnecessary in most standard-risk patients. However, high-risk patients, such as those with BCR-ABL or MLL rearrangements or high white count presentations, should still be referred for HSCT in CR-1. Minimal residual disease positivity has also been identified as a high-risk feature. Patients with BCR-ABL–positive ALL should receive combined therapy with a tyrosine kinase inhibitor and chemotherapy prior to HSCT. The adoption of pediatric-based regimens has been associated with significant additional toxicities, including venous thromboembolism, osteonecrosis, other steroid-related changes, and neuropathy, which can potentially have a major adverse impact on the quality of life of these young ALL patients.


  • A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response

    by J M Brandwein, D W Hedley, S Chow, A D Schimmer, K W L Yee, A C Schuh, V Gupta, W Xu, S Kamel-Reid, M D Minden

    This phase I/II study evaluated imatinib as a c-kit inhibitor combined with mitoxantrone, etoposide and cytarabine therapy for patients with primary refractory or relapsed c-kit+ acute myeloid leukemia (AML). Imatinib was escalated through three dose levels in successive six patient cohorts. The combination was well tolerated up to 400 mg/day imatinib. Of 21 patients treated at this dose, 13 (62%) achieved complete response (CR), 7 (33%) were non-responders and one died during induction. The CR rate was 80% in patients with standard-risk karyotype versus 33% in patients with adverse karyotype. The CR rate for primary non-responders was 6/14 (43%) versus 7/7 (100%) for relapsed patients. AML blasts from peripheral blood were assayed for phosphorylated Akt (pAkt) and phosphorylated ERK (pERK) by flow cytometry before to and after imatinib dosing. Of eight patients achieving CR with reinduction, seven demonstrated marked (60%) pAkt inhibition with imatinib therapy. In contrast, all the six non-responders to reinduction demonstrated P=0.005). There was no correlation between pERK inhibition and response to therapy. These results indicate that lack of pAkt inhibition in vivo is associated with resistance to reinduction therapy using this regimen. Further studies using agents that are able to inhibit Akt more effectively are warranted.


  • Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia

    by Murtadha Al-Khabori, Mark D. Minden, Karen W.L. Yee, Vikas Gupta, Aaron D. Schimmer, Andre C. Schuh, Wei Xu, Joseph M. Brandwein

    All patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) and treated over a 17-year period at a single institution were retrospectively analyzed. From 1990 to 2000, 40 patients were treated with a variety of adult-based ALL regimens. From 2000 to 2007, a pediatric-based protocol, DFCI (Dana Farber Cancer Institute), was used as the standard regimen for all patients (n = 32). The two groups (DFCI and non-DFCI) had comparable baseline characteristics. Complete response rates were not significantly different between the DFCI- and non-DFCI-treated groups. The 3-year relapse free survival (RFS) and overall survival (OS) were significantly higher in the DFCI-treated group (p < 0.0001 and p = 0.0003, respectively). On multivariate analysis, the treatment group (DFCI vs. non-DFCI) was the major prognostic factor influencing both RFS and OS. The results provide evidence supporting the superior efficacy of asparaginase-intensive pediatric-based regimens for adults with T-ALL.


  • Open Access

    Treatment of adults with BCR‐ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen

    by John M. Storring, Mark D. Minden, Susan Kao, Vikas Gupta, Andre C. Schuh, Aaron D. Schimmer, Karen W. L. Yee, Suzanne Kamel‐Reid, Hong Chang, Jeffrey H. Lipton, et al.

    Summary: Between 2000 and 2006, 85 adult BCR‐ABL negative acute lymphoblastic leukaemia (ALL) patients between 18 and 60 years of age were treated using a modified paediatric regimen, which included high doses of asparaginase delivered weekly for 30 weeks during intensification. The complete response rate with induction therapy was 89%, and decreased with increasing age, mainly due to higher induction mortality. All post‐induction treatments were delivered on an outpatient basis. The most common complications during intensification were infections (47%), osteonecrosis (32%), venous thromboembolism (23%) and neuropathy (22%). At a median follow‐up of 4 years, the 5‐year overall survival (OS) and relapse‐free survival (RFS) were 63% and 71%, respectively. Significant adverse predictors for OS were age >35 years, high white blood cell count, MLL rearrangement, allogeneic stem cell transplantation in first complete remission and 35 years. We conclude that the administration of this paediatric regimen is feasible and has considerable activity in adult ALL, particularly in younger patients. Effective delivery of asparaginase dosing appears to be important in achieving an optimal antileukaemic effect.


  • Open Access

    A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over

    by J M Brandwein, B F Leber, K Howson-Jan, A D Schimmer, A C Schuh, V Gupta, K W L Yee, J Wright, M Moore, K MacAlpine, et al.

    Patients aged 60 years and over with previously untreated acute myeloid leukemia were enrolled in a Phase I study combining tipifarnib with standard induction therapy. The regimen consisted of cytarabine 100 mg/m2/day continuous intravenous (i.v.) infusion on days 1–7, daunorubicin 60 mg/m2/day i.v. push × 3 on days 6–8 and tipifarnib twice daily on days 6–15. Tipifarnib was escalated over four dose levels (200, 300, 400 and 600 mg). Patients achieving complete response (CR) were eligible to receive one consolidation using the same regimen. The following dose-limiting toxicities (DLTs) were identified during induction: dose level I: 2/6 (hyperbilirubinemia, respiratory arrest), level II: 0/3, level III: 0/3 and level IV: 4/10 (one each of diarrhea, neutropenic enterocolitis, arrhythmia and delayed hematologic recovery post-consolidation). There were no DLTs due to delayed hematologic recovery post-induction. Of 22 evaluable patients, there were 10 CR, 2 morphologic leukemia-free state (MLFS), 2 partial remission (PR) and 8 non-responders. Of seven patients with adverse risk cytogenetics, there were four CR/MLFS and one PR. In summary, this regimen was well tolerated and the maximum tolerated dose was not reached, although somewhat more severe gastrointestinal toxicity was seen at dose level IV. Tipifarnib 600 mg b.i.d. is considered the recommended dose for further study using this regimen.


  • Open Access

    Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy

    by Joseph M. Brandwein, Vikas Gupta, Andre C. Schuh, Aaron D. Schimmer, Karen Yee, Wei Xu, Hans A. Messner, Jeffrey H. Lipton, Mark D. Minden

    Eighty‐one patients with acute myeloid leukemia who had persistent leukemia following standard induction therapy with cytarabine plus daunorubicin (7+3 regimen) underwent reinduction therapy with a combination of mitoxantrone, etoposide, and high‐dose cytarabine (HiDAC). Patients achieving complete remission (CR) then received consolidation therapy with HiDAC plus mitoxantrone. Patients with matched sibling donors were referred for allogeneic bone marrow transplantation (BMT) in CR‐1. The overall response rate to reinduction was 53%. The major adverse predictors of CR on multivariate analysis were poor risk cytogenetics, a higher % bone marrow blasts prior to reinduction therapy and increased age. The median relapse‐free survival (RFS) was 9 months and the estimated 2‐year RFS was 30%. No significant predictors of RFS or overall survival (OS) were found among the patients achieving CR. Patients undergoing allogeneic BMT in CR‐1 after double induction had a 50% 2‐year OS. Patients relapsing after achieving CR with double induction had a poor outcome with a 4% 1‐year OS. The results indicate that patients with poor risk cytogenetics or marrow blast percentage ≥ 60% following 7+3 induction have a low probability of achieving CR with reinduction and should be considered for novel approaches to improve CR rates. Patients achieving CR are at high risk of relapse and should be considered for allogeneic BMT or novel strategies to attempt to reduce relapse rates. Am. J. Hematol., 2008.


  • Open Access

    A phase II study of temozolomide therapy for poor-risk patients aged ⩾60 years with acute myeloid leukemia: low levels of MGMT predict for response

    by J M Brandwein, L Yang, A D Schimmer, A C Schuh, V Gupta, R A Wells, S M H Alibhai, W Xu, M D Minden